NASDAQ:RYTM - Rhythm Pharmaceuticals News Headlines

$21.94
-0.07 (-0.32 %)
(As of 06/24/2019 09:45 AM ET)
Today's Range
$21.71
Now: $21.9450
$22.12
50-Day Range
$21.95
MA: $25.02
$27.75
52-Week Range
$21.80
Now: $21.9450
$37.23
Volume9,540 shs
Average Volume135,335 shs
Market Capitalization$755.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1

Headlines

Rhythm Pharmaceuticals (NASDAQ RYTM) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Will Announce Earnings of -$0.80 Per ShareZacks: Analysts Expect Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Will Announce Earnings of -$0.80 Per Share
www.americanbankingnews.com - June 23 at 7:10 AM
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Given Average Rating of "Hold" by AnalystsRhythm Pharmaceuticals Inc (NASDAQ:RYTM) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - June 23 at 2:37 AM
Short Interest in Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Expands By 9.3%Short Interest in Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Expands By 9.3%
www.americanbankingnews.com - June 20 at 10:16 PM
Rhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of DirectorsRhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of Directors
finance.yahoo.com - June 19 at 5:35 PM
Insider Selling: Rhythm Pharmaceuticals Inc (RYTM) Insider Sells 10,000 Shares of StockInsider Selling: Rhythm Pharmaceuticals Inc (RYTM) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - June 3 at 5:15 PM
-$0.80 EPS Expected for Rhythm Pharmaceuticals Inc (RYTM) This Quarter-$0.80 EPS Expected for Rhythm Pharmaceuticals Inc (RYTM) This Quarter
www.americanbankingnews.com - May 31 at 12:19 PM
Der Ploeg Leonardus H.T. Van Sells 15,000 Shares of Rhythm Pharmaceuticals Inc (RYTM) StockDer Ploeg Leonardus H.T. Van Sells 15,000 Shares of Rhythm Pharmaceuticals Inc (RYTM) Stock
www.americanbankingnews.com - May 30 at 5:20 PM
Why Q3 Is Critical For Rhythm PharmaceuticalsWhy Q3 Is Critical For Rhythm Pharmaceuticals
seekingalpha.com - May 22 at 10:08 AM
Here’s What Hedge Funds Think About Rhythm Pharmaceuticals, Inc. (RYTM)Here’s What Hedge Funds Think About Rhythm Pharmaceuticals, Inc. (RYTM)
finance.yahoo.com - May 7 at 5:33 PM
Rhythm Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care ConferenceRhythm Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference
finance.yahoo.com - May 7 at 10:06 AM
Rhythm Pharmaceuticals Reports First Quarter 2019 Financial ResultsRhythm Pharmaceuticals Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 3 at 10:18 AM
If You Had Bought Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock A Year Ago, You Could Pocket A 10% Gain TodayIf You Had Bought Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock A Year Ago, You Could Pocket A 10% Gain Today
finance.yahoo.com - April 26 at 5:21 PM
X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of DirectorsX4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors
www.businesswire.com - April 2 at 1:06 PM
Rhythm Pharmaceuticals to Present at 18th Annual Needham Healthcare ConferenceRhythm Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
finance.yahoo.com - April 2 at 1:06 PM
Rhythm Pharmas setmelanotide shows positive action in mid-stage obesity studyRhythm Pharma's setmelanotide shows positive action in mid-stage obesity study
seekingalpha.com - March 28 at 10:38 AM
Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further DevelopmentRhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development
finance.yahoo.com - March 28 at 10:38 AM
Global Anti-Obesity Therapeutics Market Outlook, Key Trends, Opportunities, Product Quality, Competitive Analysis and Forecast 2019-2028Global Anti-Obesity Therapeutics Market Outlook, Key Trends, Opportunities, Product Quality, Competitive Analysis and Forecast 2019-2028
www.marketwatch.com - March 22 at 10:31 AM
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial ResultsRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 8 at 10:39 AM
Rhythm Pharmaceuticals to Present at Cowen & Co. 39th Annual Health Care ConferenceRhythm Pharmaceuticals to Present at Cowen & Co. 39th Annual Health Care Conference
finance.yahoo.com - March 4 at 9:52 AM
Rhythm Pharmaceuticals: Opportunity To Take Position Ahead Of Pivotal DataRhythm Pharmaceuticals: Opportunity To Take Position Ahead Of Pivotal Data
seekingalpha.com - February 1 at 10:25 AM
A Look At The Fair Value Of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)A Look At The Fair Value Of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
finance.yahoo.com - January 25 at 4:42 PM
RYTM Makes Notable Cross Below Critical Moving AverageRYTM Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - January 24 at 10:27 AM
Rhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37th Annual J.P. Morgan Healthcare ConferenceRhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 8:21 AM
Bullish Two Hundred Day Moving Average Cross - RYTMBullish Two Hundred Day Moving Average Cross - RYTM
www.nasdaq.com - December 31 at 4:09 PM
Rhythm Pharmaceuticals enrolls first patient in phase 3 trial evaluating setmelanotide in BBS and Alström SyndromeRhythm Pharmaceuticals enrolls first patient in phase 3 trial evaluating setmelanotide in BBS and Alström Syndrome
seekingalpha.com - December 13 at 8:41 AM
Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström SyndromesRhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
finance.yahoo.com - December 13 at 8:41 AM
Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl SyndromeRhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome
finance.yahoo.com - December 6 at 9:44 AM
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018
finance.yahoo.com - November 15 at 9:40 AM
Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial ResultsRhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results
finance.yahoo.com - November 9 at 10:06 AM
Rhythm Pharmaceuticals to Present at Stifel 2018 Healthcare ConferenceRhythm Pharmaceuticals to Present at Stifel 2018 Healthcare Conference
finance.yahoo.com - November 7 at 9:58 AM
Rhythm Pharmaceuticals appoints Murray W. Stewart as Chief Medical OfficerRhythm Pharmaceuticals appoints Murray W. Stewart as Chief Medical Officer
seekingalpha.com - October 15 at 9:29 AM
Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical OfficerRhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer
finance.yahoo.com - October 15 at 9:29 AM
This Day That Year: Rhythm PharmaThis Day That Year: Rhythm Pharma
www.nasdaq.com - October 5 at 9:38 AM
Commit To Purchase Rhythm Pharmaceuticals At $25, Earn 18.5% Annualized Using OptionsCommit To Purchase Rhythm Pharmaceuticals At $25, Earn 18.5% Annualized Using Options
www.nasdaq.com - October 3 at 4:00 PM
Rhythm Pharmaceuticals (RYTM) Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating SetmelanotideRhythm Pharmaceuticals (RYTM) Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide
www.streetinsider.com - September 28 at 4:04 PM
Updated data show continued reductions in body weight and decreased appetite in patients with rare genetic disorders of obesityUpdated data show continued reductions in body weight and decreased appetite in patients with rare genetic disorders of obesity
globenewswire.com - September 28 at 9:43 AM
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE MeetingRhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting
finance.yahoo.com - September 28 at 9:43 AM
Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of ObesityRhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
finance.yahoo.com - September 28 at 9:43 AM
Rhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare ConferenceRhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference
finance.yahoo.com - September 25 at 9:45 AM
Rhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare ConferenceRhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare Conference
finance.yahoo.com - September 7 at 9:42 AM
Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial ResultsRhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results
finance.yahoo.com - August 9 at 10:09 AM
Rhythm Pharmaceuticals (RYTM) Receives EMA PRIME Designation for Setmelanotide in Rare Genetic Disorders of ObesityRhythm Pharmaceuticals (RYTM) Receives EMA PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
www.streetinsider.com - July 24 at 10:12 AM
Rhythm Pharmas setmelanotide a PRIME drug in Europe for rare genetic disorders of obesityRhythm Pharma's setmelanotide a PRIME drug in Europe for rare genetic disorders of obesity
seekingalpha.com - July 23 at 3:45 PM
Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of ObesityRhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
finance.yahoo.com - July 23 at 9:38 AM
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesRhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - June 25 at 4:03 PM
Here's Why Rhythm Pharmaceuticals Inc Rose as Much as 37% TodayHere's Why Rhythm Pharmaceuticals Inc Rose as Much as 37% Today
finance.yahoo.com - June 21 at 4:03 PM
Heres Why Rhythm Pharmaceuticals Inc Rose as Much as 37% TodayHere's Why Rhythm Pharmaceuticals Inc Rose as Much as 37% Today
www.fool.com - June 21 at 3:46 PM
Rhythm Pharmaceuticals announces pricing of public offeringRhythm Pharmaceuticals announces pricing of public offering
seekingalpha.com - June 21 at 11:32 AM
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public OfferingRhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
finance.yahoo.com - June 21 at 11:32 AM
Milestone Pharmaceuticals Announces Launch of OutsmartPSVT.com Supporting Patients with PSVT, a Common and Underdiagnosed Heart DisorderMilestone Pharmaceuticals Announces Launch of OutsmartPSVT.com Supporting Patients with PSVT, a Common and Underdiagnosed Heart Disorder
www.bizjournals.com - June 19 at 12:01 PM
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel